• 1
    Zhang J, Liu WL, Tang DC, et al. Identification and characterization of a novel member of olfactomedin-related protein family, hGC-1, expressed during myeloid lineage development. Gene. 2002; 283: 8393.
  • 2
    Zhang X, Huang Q, Yang Z, et al. GW112, a novel antiapoptotic protein that promotes tumor growth. Cancer Res. 2004; 64: 247481.
  • 3
    Liu W, Zhu J, Cao L, et al. Expression of hGC-1 is correlated with differentiation of gastric carcinoma. Histopathology. 2007; 51: 15765.
  • 4
    Liu W, Liu Y, Zhu J, et al. Reduced hGC-1 protein expression is associated with malignant progression of colon carcinoma. Clin Cancer Res. 2008; 14: 10419.
  • 5
    Oue N, Sentani K, Noguchi T, et al. Serum olfactomedin 4 (GW112, hGC-1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients. Int J Cancer. 2009; 125: 238392.
  • 6
    Marimuthu A, Chavan S, Sathe G, et al. Identification of head and neck squamous cell carcinoma biomarker candidates through proteomic analysis of cancer cell secretome. Biochim Biophys Acta. 2013; 1834: 230816.
  • 7
    Makawita S, Smith C, Batruch I, et al. Integrated proteomic profiling of cell line conditioned media and pancreatic juice for the identification of pancreatic cancer biomarkers. Mol Cell Proteomics. 2011; 10: M111 008599.
  • 8
    Yan H, Lu D, Xu L, et al. Increased expression level of Olfactomedin4 in peripheral blood mononuclear cells of pancreatic adenocarcinoma patients. Hepatogastroenterology. 2011; 58: 13549.
  • 9
    Besson D, Pavageau AH, Valo I, et al. A quantitative proteomic approach of the different stages of colorectal cancer establishes OLFM4 as a new nonmetastatic tumor marker. Mol Cell Proteomics. 2011; 10: M111 009712.
  • 10
    Huang MY, Wang HM, Chang HJ, et al. Overexpression of S100B, TM4SF4, and OLFM4 genes is correlated with liver metastasis in Taiwanese colorectal cancer patients. DNA Cell Biol. 2012; 31: 439.
  • 11
    Huang MY, Wang HM, Tok TS, et al. EVI2B, ATP2A2, S100B, TM4SF3, and OLFM4 as potential prognostic markers for postoperative Taiwanese colorectal cancer patients. DNA Cell Biol. 2012; 31: 62535.
  • 12
    van der Flier LG, Haegebarth A, Stange DE, et al. OLFM4 is a robust marker for stem cells in human intestine and marks a subset of colorectal cancer cells. Gastroenterology. 2009; 137: 157.
  • 13
    van der Flier LG, van Gijn ME, Hatzis P, et al. Transcription factor achaete scute-like 2 controls intestinal stem cell fate. Cell. 2009; 136: 90312.
  • 14
    Kobayashi D, Koshida S, Moriai R, et al. Olfactomedin 4 promotes S-phase transition in proliferation of pancreatic cancer cells. Cancer Sci. 2007; 98: 33440.
  • 15
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 1029.
  • 16
    Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control. 2009; 16: 813.
  • 17
    Cerezo L, Cardenes H, Michael H. Molecular alterations in the pathogenesis of endometrial adenocarcinoma. Therapeutic implications. Clin Transl Oncol. 2006; 8: 23141.
  • 18
    Cui Z, Zhang L, Hua Z, et al. Stomatin-like protein 2 is overexpressed and related to cell growth in human endometrial adenocarcinoma. Oncol Rep. 2007; 17: 82933.
  • 19
    Yang Y, Zhou L, Lu L, et al. A novel miR-193a-5p-YY1-APC regulatory axis in human endometrioid endometrial adenocarcinoma. Oncogene. 2013; 32: 343242.
  • 20
    Dassen H, Punyadeera C, Delvoux B, et al. Olfactomedin-4 regulation by estrogen in the human endometrium requires epidermal growth factor signaling. Am J Pathol. 2010; 177: 2495508.
  • 21
    Yu L, He M, Yang Z, et al. Olfactomedin 4 is a marker for progression of cervical neoplasia. Int J Gynecol Cancer. 2011; 21: 36772.
  • 22
    Murray D, Doran P, MacMathuna P, et al. In silico gene expression analysis–an overview. Mol Cancer. 2007; 6: 50.
  • 23
    Pontius JUWL, Schuler GD. Unigene: a unified view of the transcriptome. Bethesda, MD: NCBI; 2003.
  • 24
    Scheurle D, DeYoung MP, Binninger DM, et al. Cancer gene discovery using digital differential display. Cancer Res. 2000; 60: 403743.
  • 25
    Yu L, Wang L, Li M, et al. Expression of toll-like receptor 4 is down-regulated during progression of cervical neoplasia. Cancer Immunol Immunother. 2010; 59: 10218.
  • 26
    Yu L, Wang L, Chen S. Olfactomedin 4, a novel marker for the differentiation and progression of gastrointestinal cancers. Neoplasma. 2011; 58: 913.
  • 27
    Kim KK, Park KS, Song SB, et al. Up regulation of GW112 Gene by NFkappaB promotes an antiapoptotic property in gastric cancer cells. Mol Carcinog. 2010; 49: 25970.
  • 28
    Park KS, Kim KK, Piao ZH, et al. Olfactomedin 4 suppresses tumor growth and metastasis of mouse melanoma cells through downregulation of integrin and MMP genes. Mol Cells. 2012; 34: 55561.
  • 29
    Chen L, Li H, Liu W, et al. Olfactomedin 4 suppresses prostate cancer cell growth and metastasis via negative interaction with cathepsin D and SDF-1. Carcinogenesis. 2011; 32: 98694.
  • 30
    Liu W, Lee HW, Liu Y, et al. Olfactomedin 4 is a novel target gene of retinoic acids and 5-aza-2′-deoxycytidine involved in human myeloid leukemia cell growth, differentiation, and apoptosis. Blood. 2010; 116: 493847.
  • 31
    Liu W, Chen L, Zhu J, et al. The glycoprotein hGC-1 binds to cadherin and lectins. Exp Cell Res. 2006; 312: 178597.
  • 32
    Seko N, Oue N, Noguchi T, et al. Olfactomedin 4 (GW112, hGC-1) is an independent prognostic marker for survival in patients with colorectal cancer. Exp Ther Med. 2010; 1: 738.
  • 33
    Luo Z, Zhang Q, Zhao Z, et al. OLFM4 is associated with lymph node metastasis and poor prognosis in patients with gastric cancer. J Cancer Res Clin Oncol. 2011; 137: 171320.
  • 34
    Takadate T, Onogawa T, Fukuda T, et al. Novel prognostic protein markers of resectable pancreatic cancer identified by coupled shotgun and targeted proteomics using formalin-fixed paraffin-embedded tissues. Int J Cancer. 2013; 132: 136882.